Fig. 3

ACBP/DBI neutralization improves immunosurveillance of NSCLC in mice. Anti-ACBP/DBI mAb or isotype-matched control mAb was repeatedly injected intraperitoneally (i.p.), starting two days before intravenous (i.v.) injection of TC1 NSCLC cells expressing luciferase (TC1-Luc) into immunocompetent C57Bl/6 mice (A). Anti-ACBP/DBI mAb reduced the progression of orthotopic NSCLC cancers developing in the thoracic cage, as determined by chemoluminescence imaging (B, C). Alternatively, ACBP/DBI neutralization was performed in immunodeficient Hsd:Athymic Nude-Foxn1nu mice starting from tumor detection (D). Repeated injections of anti-ACBP/DBI mAb failed to slow down tumor progression in these athymic animals (E). In immunocompetent C57Bl/6 mice bearing orthotopic NSCLC (TC1-Luc), neutralization of ACBP/DBI was achieved by recurrent injections of monoclonal antibody (mAb) during chemoimmunotherapy (CT + anti-PD1), following the schedule (F). Tumor growth was monitored in situ by bioluminescent imaging (G). ACBP/DBI neutralization improved mouse survival both with and without chemoimmunotherapy (H) by slowing down tumor growth (I). Individual longitudinal tumor growth curves from two independent experiments are displayed in the background, the group tendencies are represented by locally weighted scatterplot smoothing curves (5 points per smoothing window). Statistical comparisons were performed by log-rank (Mantel-Cox) tests for survival and by 2-way ANOVA after log-transformation for tumor bioluminescence